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Abstract
Objective
To describe a patient with a multifocal demyelinating motor neuropathy with onset in child-
hood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene
associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor,
and epilepsy. Functional implications of this protein have been investigated in Parkinson and
Alzheimer diseases.
Methods
We performed whole-exome sequencing in the patient’s genomic DNA validated by Sanger
sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic proﬁling
were performed in the patient’s ﬁbroblasts.
Results
The predominant clinical presentation of the patient was a childhood onset, asymmetric pro-
gressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism
spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related
hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We
detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent
in both parents. The pathogenicity of the variant is supported by altered expression of several
PTEN-associated proteins involved in tumorigenesis. Moreover, ﬁbroblasts showed a defect in
catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate.
In support of our ﬁndings, focal hypermyelination leading to peripheral neuropathy has been
reported in PTEN-deﬁcient mice.
Conclusion
We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy
with a skin hamartoma syndrome. A similar mechanismmay potentially underlie other forms of
Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway.
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Inherited peripheral neuropathies (Charcot-Marie-Tooth dis-
ease [CMT]) encompass genetically heterogeneous sensory or
motor nerve conditions.1 Next generation sequencing2 and
proteomics3 are powerful and robust methodologic approaches
to elucidate the underlying molecular cause and pathologic
mechanisms.
Phosphatase and tensin homolog located on chromosome 10
(PTEN) is a tumor suppressor gene in which mutations are
typically found in sporadic cancers and inherited tumor sus-
ceptibility conditions, such as the PTEN hamartoma tumor
syndrome (PHTS). Macrocephaly, autism spectrum disorder
(ASD), ataxia, tremor, and epilepsy have been reported in
patients with PTENmutations, while functional implications of
this protein have been investigated in Parkinson and Alzheimer
diseases.4,5 Various PTEN functions in neurons have been
linked to its dynamic spatiotemporal distribution. Regulation
of neuronal cell size, axonal outgrowth, synaptogenesis, and
neuromuscular assembly are PTEN-controlled processes dur-
ing neuronal development and regeneration after injury. Fur-
thermore, in PTEN-deﬁcient mice abnormal regulation of
myelination has been observed in peripheral nerves.6,7
Here we describe a patient manifesting with multifocal de-
myelinating motor neuropathy and hamartoma syndrome in
association with a de novo heterozygous PTEN mutation.
Methods
A 29-year-old patient had been born to nonconsanguineous
Caucasian parents. Delayed motor development and speech
were reported with facial asymmetry at 7 years of age. He
developed focal weakness involving his right eye movements,
his face, and contralateral extremities in the following years.
By age 20, multiple livid papules and keloid scars appeared on
his chest and he had bowel problems and learning diﬃculties.
Examination at age 29 revealed a large scaphocephalic head
(macrocephaly), asymmetric face, and crowded teeth. The
patient had upper thoracic scoliosis. Right oculomotor palsy,
complete right-sided and partial left-sided facial palsy, and left-
sided tongue atrophy were noted. He had nasal speech. There
was both proximal and distal ﬂaccid paresis in the left upper
limb, with atrophy and areﬂexia. In the right arm, he had
proximal ﬂexor weakness but preserved distal grip strength.
The right leg was short with pes cavus and hammertoes along
with distal motor weakness and atrophy. The left leg showed no
wasting and only mildly decreased strength in foot extensors.
Knee jerk reﬂexes were brisk bilaterally, but ankle jerk reﬂexes
were absent. Sensory examination was normal. There was no
cerebellar ataxia, but he had learning diﬃculties.
Nerve conduction studies showed markedly reduced asym-
metric compound muscle action potential responses with dis-
persion and conduction slowing and signiﬁcant conduction
block at multiple sites fulﬁlling the AAEM 2003 criteria for
deﬁnite multifocal motor neuropathy (ﬁgure 1, B and C).
Sensory responses were within acceptable limits throughout. On
EMG, neurogenic changes were observed in the wasted limbs
but no evidence of recent denervation was found except in right
deltoid on the most recent EMG requested after the patient
complained of new onset shoulder weakness (tables e-1–e-4,
links.lww.com/WNL/A481).
Imaging and laboratory studies including CSF were repeatedly
unremarkable. Routine genetic diagnostic testing revealed
normal CGH array and no pathogenic variants were detected
on the next-generation panel for 56 genes associated with
CMT.2 Immunosuppressive therapy was tried without beneﬁt.
We performedwhole exome sequencing in the patient’s genomic
DNA.2 Variants were annotated and ﬁltered against protein
prediction, evolutionary conservation, and frequency in several
databases and were validated by Sanger sequencing and segre-
gation analysis in the patient and in his parents with special
attention on variants in all known CMT-related genes. Immu-
noblotting was performed in ﬁbroblasts by standard techniques.
Enzyme function test was carried out using in vitro malachite
green phosphatase assay as described.7 Label-free shotgun pro-
teomic proﬁling utilizing patient-derived (4 biological replicates)
and control ﬁbroblasts (6 biological replicates) was performed
(e-Methods, links.lww.com/WNL/A482).
Data availability
Whole exome sequencing data of the patient has been de-
posited in RD-CONNECT (rd-connect.eu/) and in the Eu-
ropean Genome Phenome Archive (ega-archive.org/). The
mass spectrometry data has been deposited to the Proteo-
meXchange Consortium31 via the PRIDE partner repository
with data identiﬁer PXD008014 (proteomecentral.proteo-
mexchange.org/cgi/GetDataset).
Results
The patient carried a novel de novo heterozygous c.269T>C,
p.(Phe90Ser) PTEN variant, which was absent in both parents
Glossary
ASD = autism spectrum disorder; CMT = Charcot-Marie-Tooth disease; HNPP = hereditary neuropathy with liability to
pressure palsies; PHTS = PTEN hamartoma tumor syndrome; PI(3)K = phosphoinositide 3-kinase; PI(3,4)P2 =
phosphatidylinositol 3,4,-trisphosphate; PIP3 = phosphatidylinositol 3,4,5-trisphosphate; PTEN = phosphatase and tensin
homolog located on chromosome 10.
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Figure 1 Clinical and electrophysiologic features
(A) Photographs of the patient show the asymmetric focal neuropathy. (B) Right abductor pollicis brevis (APB) compound muscle action potentials (CMAPs)
obtained by stimulating themedian nerve at the wrist (top), the antecubital fossa (middle), and above the elbow (bottom) demonstrate significant conduction
block (with desynchronization) affecting the rightmedian nervewithin the forearm. In the lower traces, proximal responses (black lines) are superimposed on
the distal CMAP (plotted in gray), thus facilitating visualization of the conduction block at each location (the percentage drop in CMAP amplitude at each site is
also indicated). (C) Right abductor digiti minimi (ADM) CMAPs evoked by stimulating the ulnar nerve at the wrist (top) and below (middle) and above (bottom)
the medial epicondyle demonstrate significant conduction block (with dispersion) affecting the right ulnar nerve within the forearm. Maximal distal CMAPs
were obtained using stimulus currents of ;10 mA and to confirm conduction block currents of ;25 mA were used at proximal locations (pulse duration
0.5ms). Stimulus artefacts have been removed for clarity. Arrowheadsmark CMAP onset. *Significantly higher stimulus currents (up to 100mA) were used to
confirm conduction block during clinical testing. (D) Electropherogram shows the de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN mutation. (E) Evolu-
tionary conservation of the mutation.
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(ﬁgure 1D). The mutation has not been reported in the ExAc
database and it aﬀects a highly conserved amino acid residue
within the catalytic site of PTEN phosphatase domain and
was predicted to be deleterious.
Immunoblotting revealed normal levels of PTEN in the
patient’s ﬁbroblasts (ﬁgure 2, A and B). Enzyme function
assay revealed no impaired p.(Phe90Ser) PTEN phosphatase
activity on phosphatidylinositol 3,4,5-trisphosphate (PIP3) as
a substrate when compared the wild-type protein. However,
there was a defect in catalytic activity against the secondary
substrate of PTEN, phosphatidylinositol 3,4-trisphosphate
(PI[3,4]P2), which was no longer apparent at high levels of
PI(3,4)P2 (ﬁgure 2, C and D).
Proteomic proﬁling in patient-derived ﬁbroblasts revealed
a total of 1,944 distinct proteins with altered abundance of 47
(9 proteins based on 2 or more peptides, 38 proteins on one
unique peptide) with diﬀerent subcellular localizations such as
cytosol and cell membrane (ﬁgure 3 and ﬁgure e-1, links.lww.
com/WNL/A480; e-Methods, links.lww.com/WNL/A482).
LMCD1 and ITA3 are associated with cell migration and
metastasis formation,8 while AK2, ILK, and SBP1 are involved
in cellular antitumor response.9,10
Discussion
GermlinePTENmutations cause various human conditions with
poorly understood genotype–phenotype correlations.4,11 PTEN
shows limited genetic variation in the human population (1000
Genome Project found 54 single nucleotide variants with minor
allele frequency <0.001) and the protein is highly conserved
between species. Cytosolic PTEN consists of 403 amino acids
divided into anN-terminal phosphatase domain (7–185), a lipid-
bindingC2 domain (186–351), and aC-terminal tail (352–403),
containing phosphorylation sites that regulate protein activity
and stability.11 PTEN directly antagonizes Class I phosphoino-
sitide 3-kinases (PI[3]Ks) by converting PIP3 into phosphati-
dylinositol 4,5-bisphosphate (PI[4,5]P2). Diminished PI(3)K
signaling exerts a brake on downstream eﬀector pathways in-
terfering with cellular processes such as cell growth, proliferation,
and survival.5,11 The alternate PTEN substrate, PI(3,4)P2, has
many similar signaling functions to PIP3 and several tumors are
caused by preferential loss of hydrolysis of PI(3,4)P2 substrates
12
and depending on its subcellular location PI(3,4)P2 is both
a suppressor and enhancer of mTOR signaling.13
Loss of function germline mutations in PTEN are mainly
associated with inherited tumors and severe PHTS, while
retained or partially lost PTEN activity has been found in
neurodevelopmental disorders.4 Besides its dual-speciﬁc
phosphatase activity, phosphatase-independent mechanisms
and protein–protein interactions have also been implicated in
PTEN mutations.5
The p.(Phe90Ser) missense change identiﬁed in our patient is
located within the WPD loop, which is equally near to the
phosphatase active pocket and to the membrane-binding
regulatory interface of the PTEN C2 domain. Most of the
mutatedWPD residues have been considered not to inﬂuence
or to only partially aﬀect PTEN catalytic activity.14 The so-
matic p.(Phe90Ser) PTENmutation has been found in cancer
(glioma, endometrium), and had normal phosphatase activity
against PIP3 but a reduced ability to bind membrane phos-
pholipids and recruit PTEN for PIP3 signalling.
7 The germ-
line c.269T>C, p.(Phe90Ser) PTENmutation in ﬁbroblasts of
our patient produced a stable protein with an unexpected
deﬁcit in activity against PI(3,4)P2. This may be due to a novel
allostery in the mutant or a change in the vulnerability of the
protein to oxidation, which inhibits PTEN activity in these
assays. In agreement with our data, a recent publication
conﬁrmed that PTEN is a PI(3,4)P2 3-phosphatase and to-
gether with INPP4B regulates PI(3,4)P2 accumulation
downstream of Class I PI3K, and PI(3,4)P2 signaling may play
a role in the tumor suppressor function of PTEN.15
The phenotype of this patient was unique and diﬀerent from
the neurologic presentations associated with PTEN defects
reported previously. Extensive tumor screening did not detect
any malignancies, but we considered his hypertrophic keloids
as skin hamartomas. While fulﬁlling some of the clinical criteria
of PHTS, including the presence of macrocephaly, skin lesions,
and ASD, the predominant feature at presentation was an
asymmetric, gradually progressive multifocal demyelinating
motor neuropathy, with electrophysiologic evidence of deﬁnite
partial conduction block fulﬁlling American Academy of Elec-
trodiagnostic Medicine diagnostic criteria for multifocal motor
neuropathy.16 A susceptibility to demyelination following mild
trauma—similar to hereditary neuropathy with liability to
pressure palsies (HNPP)—might explain the multifocal pre-
sentation in this disorder. In support of this theory, in a mouse
model with targeted mutation of PTEN in Schwann cells,
progressive peripheral neuropathy with focal hypermyelination,
myelin outfoldings, and “tomacula” formation has been
reported, showing striking similarities to the pathologic ﬁnd-
ings in HNPP.6 A similar clinical presentation with rapidly
progressive asymmetric demyelinating neuropathy with con-
duction blocks and temporal dispersion aﬀecting one limb,
resembling an acquired inﬂammatory neuropathy, has been
described in a patient with a FIG4mutation, another rare cause
of inherited demyelinating related to abnormal levels of PI 3-
phosphates.17 Furthermore, transheterozygous PTEN mutant
Drosophila melanogaster have been found to have progressive
motor function loss, with deﬁcits in climbing and ﬂight ability.18
Several genetic forms of CMT have been described with ab-
normal myelin histopathology and tomacula formation
(CMT4B, CMT4H, CMT4F, CMT1B, and HNPP).1 The
causative proteins contain phosphoinositide binding domains
in CMT2B/RAB7, CMT4B1/MTMR2, CMT4B2/SBF2,
CMT4J/FIG4, and CMT4H/FGD4, suggesting that abnor-
mal PI(3)K signaling is a common ﬁnal pathway in de-
myelinating CMT (ﬁgure 2E). Changes in phosphoinositide
metabolites can have many possible cellular eﬀects interfering
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Figure 2 Functional effects of abnormal phosphatase and tensin homolog located on chromosome 10 (PTEN)
(A) Immunoblot (with marker size in kDa) shows expression of PTEN in fibroblasts from 2 controls (C1, C2) and the patient. (B) Quantification of mean
relative PTEN expression between controls (C1, C2) and patient fibroblasts (3 replicates). (C) PTENC124S but not PTENF90S shows reduced enzymatic
activity against 150 μMPI(2,4,5)P3 and 200 μMPI(3,4)P2 compared to PTEN
WT. (D) PTENF90S shows reduced activity against <100 μMPI(3,4)P2 compared
to PTENWT. (E) The roles of PTENwithin the phosphatidylinositol system, with humanmutations causing neuropathy and cancer highlighted according
to the key.
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with normal myelinmaintenance and the enzymes involved or
their downstream targets are appealing therapeutic targets.
Selective inhibition of PI(3)K is a novel anticancer therapy
approach already in clinical trials with favorable toxicity pro-
ﬁle.19 Metabolomic studies of the same inhibitor show that
plasma metabolites can be useful dose-dependent biomarkers
of the response to therapy.20
Results of our proteomic proﬁling allowed the identiﬁcation of
several proteins supporting abnormal PTEN function: increased
Figure 3 Proteomic profiling
Proteomic profiling in patient-de-
rived fibroblasts revealed a total of
1,944 distinct proteins with altered
abundance of 47 proteins.
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LMCD1 has been linked to tumor metastasis8 and ITA3 is
involved in promoting cell invasion.21 In addition, we detected
increased AK2, a negative regulator of tumor cell growth,9 in-
dicating a compensatory eﬀect, and may explain why extensive
tumor screen did not detect malignant processes in our patient.
In the same context, increased SBP1 may act as a tumor sup-
pressor.10 Alteration of ITA3 and ILK suggests that integrin
stimulation is a downstream eﬀect of PTEN.22We found several
proteins, including GPC1, which are known to be regulated by
PTEN activity and linked to peripheral myelination and axon
guidance.
Our data revealed changes in expression of several proteins
involved in tumorigenesis or tumor suppression, supporting
a pathogenic role for the PTEN mutation, which may have
caused the focal demyelinating motor neuropathy in associ-
ation with a cutaneous hamartoma syndrome in our patient.
We detected a concentration-dependent defect in catalytic
activity of PTEN against its secondary substrate, PI(3,4)P2,
which may lead to multifocal demyelinating motor neuropa-
thy in PTEN mutations and potentially in other CMTs with
similar pathomechanisms.
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